Mo­men­ta hit with a set­back as pan­cre­at­ic can­cer drug flops in PhII

Mo­men­ta Phar­ma­ceu­ti­cals has been hit with a set­back. The Cam­bridge, MA-based biotech says that its Phase II study match­ing the ex­per­i­men­tal necu­paranib with Abrax­ane …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.